CN117679355A - 达原饮在制备抑制emt的药物中的应用 - Google Patents
达原饮在制备抑制emt的药物中的应用 Download PDFInfo
- Publication number
- CN117679355A CN117679355A CN202311368280.7A CN202311368280A CN117679355A CN 117679355 A CN117679355 A CN 117679355A CN 202311368280 A CN202311368280 A CN 202311368280A CN 117679355 A CN117679355 A CN 117679355A
- Authority
- CN
- China
- Prior art keywords
- emt
- parts
- dayuan
- cad
- beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013361 beverage Nutrition 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 20
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 41
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 41
- 230000014509 gene expression Effects 0.000 claims abstract description 35
- 102000008186 Collagen Human genes 0.000 claims abstract description 17
- 108010035532 Collagen Proteins 0.000 claims abstract description 17
- 229920001436 collagen Polymers 0.000 claims abstract description 17
- 210000002919 epithelial cell Anatomy 0.000 claims abstract description 15
- 208000005069 pulmonary fibrosis Diseases 0.000 claims abstract description 14
- 108010065472 Vimentin Proteins 0.000 claims abstract description 12
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 12
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 12
- 102000013127 Vimentin Human genes 0.000 claims abstract description 10
- 210000005048 vimentin Anatomy 0.000 claims abstract description 10
- 210000004881 tumor cell Anatomy 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims description 30
- 238000002156 mixing Methods 0.000 claims description 16
- 244000080767 Areca catechu Species 0.000 claims description 15
- 235000006226 Areca catechu Nutrition 0.000 claims description 15
- 241001673966 Magnolia officinalis Species 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 15
- 239000003112 inhibitor Substances 0.000 claims description 15
- 101150083915 cdh1 gene Proteins 0.000 claims description 12
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 10
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 10
- 244000236658 Paeonia lactiflora Species 0.000 claims description 10
- 235000008598 Paeonia lactiflora Nutrition 0.000 claims description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 235000011538 Arachis prostrata Nutrition 0.000 claims description 9
- 235000011477 liquorice Nutrition 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 8
- 239000011230 binding agent Substances 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 239000000945 filler Substances 0.000 claims description 6
- 239000000796 flavoring agent Substances 0.000 claims description 6
- 235000013355 food flavoring agent Nutrition 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000004094 surface-active agent Substances 0.000 claims description 6
- 239000000375 suspending agent Substances 0.000 claims description 6
- 239000000080 wetting agent Substances 0.000 claims description 6
- 244000025254 Cannabis sativa Species 0.000 claims description 5
- 235000006484 Paeonia officinalis Nutrition 0.000 claims description 5
- 241001106477 Paeoniaceae Species 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000007884 disintegrant Substances 0.000 claims description 5
- 239000003995 emulsifying agent Substances 0.000 claims description 5
- 239000003623 enhancer Substances 0.000 claims description 5
- 230000005012 migration Effects 0.000 claims description 5
- 238000013508 migration Methods 0.000 claims description 5
- 230000012292 cell migration Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 229940123713 vimentin inhibitor Drugs 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 2
- 241000050051 Chelone glabra Species 0.000 claims 1
- 241000412357 Triteleia laxa Species 0.000 claims 1
- 238000010298 pulverizing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 17
- 239000005644 Dazomet Substances 0.000 abstract description 6
- QAYICIQNSGETAS-UHFFFAOYSA-N dazomet Chemical compound CN1CSC(=S)N(C)C1 QAYICIQNSGETAS-UHFFFAOYSA-N 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 abstract description 4
- 238000002474 experimental method Methods 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 210000004072 lung Anatomy 0.000 description 38
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 27
- 210000001519 tissue Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 26
- 241000699670 Mus sp. Species 0.000 description 25
- 238000000605 extraction Methods 0.000 description 24
- 210000002966 serum Anatomy 0.000 description 15
- 239000002609 medium Substances 0.000 description 13
- 230000000144 pharmacologic effect Effects 0.000 description 13
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 9
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 9
- 229960002591 hydroxyproline Drugs 0.000 description 9
- 238000000465 moulding Methods 0.000 description 9
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 9
- 244000105298 Arachis prostrata Species 0.000 description 8
- 108010006654 Bleomycin Proteins 0.000 description 8
- 229960001561 bleomycin Drugs 0.000 description 8
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 229920004934 Dacron® Polymers 0.000 description 5
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical group C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 5
- 229960003957 dexamethasone Drugs 0.000 description 5
- 239000005020 polyethylene terephthalate Substances 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000207929 Scutellaria Species 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 238000003916 acid precipitation Methods 0.000 description 4
- 239000003513 alkali Substances 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000874 microwave-assisted extraction Methods 0.000 description 4
- 238000005325 percolation Methods 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 238000007670 refining Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000011347 resin Substances 0.000 description 4
- 229920005989 resin Polymers 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 238000002137 ultrasound extraction Methods 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 108010013198 Daptomycin Proteins 0.000 description 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010056342 Pulmonary mass Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 description 3
- 229960005484 daptomycin Drugs 0.000 description 3
- 238000003125 immunofluorescent labeling Methods 0.000 description 3
- 238000011532 immunohistochemical staining Methods 0.000 description 3
- 201000005202 lung cancer Diseases 0.000 description 3
- 208000020816 lung neoplasm Diseases 0.000 description 3
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 210000004879 pulmonary tissue Anatomy 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 102000000905 Cadherin Human genes 0.000 description 2
- 108050007957 Cadherin Proteins 0.000 description 2
- 102100025805 Cadherin-1 Human genes 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229960003321 baicalin Drugs 0.000 description 2
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 2
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000008176 lyophilized powder Substances 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- AEDDIBAIWPIIBD-ZJKJAXBQSA-N mangiferin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=C(OC=2C(=CC(O)=C(O)C=2)C2=O)C2=C1O AEDDIBAIWPIIBD-ZJKJAXBQSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LPLVUJXQOOQHMX-MOGLOQIBSA-N (2s,3s,4s,5r,6r)-6-[(2r,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-MOGLOQIBSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 238000011814 C57BL/6N mouse Methods 0.000 description 1
- 208000025721 COVID-19 Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
- 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 241000779783 Darwinia Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241001199075 Dichelostemma capitatum Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010015719 Exsanguination Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 description 1
- YWQSXCGKJDUYTL-UHFFFAOYSA-N Mangiferin Natural products CC(CCC=C(C)C)C1CC(C)C2C3CCC4C(C)(C)CCCC45CC35CCC12C YWQSXCGKJDUYTL-UHFFFAOYSA-N 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001601 blood-air barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- HXGBXQDTNZMWGS-RUZDIDTESA-N darifenacin Chemical compound C=1C=CC=CC=1C([C@H]1CN(CCC=2C=C3CCOC3=CC=2)CC1)(C(=O)N)C1=CC=CC=C1 HXGBXQDTNZMWGS-RUZDIDTESA-N 0.000 description 1
- 229960002677 darifenacin Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- GVGUFUZHNYFZLC-UHFFFAOYSA-N dodecyl benzenesulfonate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(=O)(=O)C1=CC=CC=C1 GVGUFUZHNYFZLC-UHFFFAOYSA-N 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000001685 glycyrrhizic acid Substances 0.000 description 1
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940043357 mangiferin Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 230000014306 paracrine signaling Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000008529 pathological progression Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 238000012257 pre-denaturation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910021487 silica fume Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080264 sodium dodecylbenzenesulfonate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- SORUXVRKWOHYEO-UHFFFAOYSA-N timosaponin B-II Natural products O1C(CO)C(O)C(O)C(O)C1OCC(C)CCC(C(C1C2(C)CCC3C4(C)CC5)C)(O)OC1CC2C3CCC4CC5OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O SORUXVRKWOHYEO-UHFFFAOYSA-N 0.000 description 1
- UDUSTUNNFSNCPR-QFNYSWOCSA-N timosaponin BII Natural products C[C@H](CC[C@@]1(O)O[C@H]2C[C@H]3[C@@H]4CC[C@@H]5C[C@H](CC[C@]5(C)[C@H]4CC[C@]3(C)[C@H]2[C@@H]1C)O[C@@H]6O[C@H](CO)[C@H](O)[C@H](O)[C@H]6O[C@@H]7O[C@H](CO)[C@@H](O)[C@H](O)[C@H]7O)[C@@H]8O[C@H](CO)[C@@H](O)[C@H](O)[C@H]8O UDUSTUNNFSNCPR-QFNYSWOCSA-N 0.000 description 1
- SORUXVRKWOHYEO-UJDJZYEZSA-N timosaponin bii Chemical compound O([C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1C[C@H]2CC[C@H]3[C@@H]4C[C@@H]5O[C@]([C@H]([C@@H]5[C@@]4(C)CC[C@@H]3[C@@]2(C)CC1)C)(O)CC[C@H](C)CO[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SORUXVRKWOHYEO-UJDJZYEZSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明属于中医药技术领域,公开了达原饮在制备抑制EMT的药物中的应用。本发明首次公开了达原饮在制备抑制EMT的药物中的应用,通过实验证明,达原饮可有效促进发生EMT的上皮细胞中CDH1基因和E‑cad蛋白的表达,抑制发生EMT的上皮细胞中N‑cad、Vimentin、α‑SMA蛋白的表达。抑制肿瘤细胞发生EMT,降低肿瘤细胞迁移率;抑制肺纤维化过程中EMT的发生,抑制胶原蛋白的合成,即达原饮可通过抑制EMT用于预防和/或治疗EMT相关疾病,为EMT相关疾病的预防和治疗提供新的可能。
Description
技术领域
本发明属于中医药技术领域,具体涉及达原饮在制备抑制EMT的药物中的应用。
背景技术
上皮间质转化(Epithelial to mesenchymal transition,EMT)是上皮细胞下调其上皮特征,获得间充质细胞表型的动态转化过程。肿瘤细胞通过EMT丢失某些上皮细胞特征来获得更强的侵袭和迁移能力,促进肿瘤的发生、侵袭和转移,增强其耐药性。同样各种亚临床迁延性损伤因素首先累及肺泡上皮,诱导肺泡上皮细胞发生EMT,发生EMT的肺上皮细胞参与肺组织过度修复,促进肺纤维化进展。
旁分泌信号分子TGF-β1等下调上皮细胞E-钙粘蛋白(E-cadherin,E-cad)的表达,破坏细胞连接是EMT发生的关键。EMT发生的组织学鉴定标准为:丢失E-cad蛋白等上皮细胞黏附分子,增加N-cad、Vimentin、α-SMA蛋白等间充质细胞的标志蛋白的表达。
达原饮是“开达膜原”的经典方剂,已用于治疗SARS的“邪伏膜原”证和COVID-19的“湿邪郁肺”证。除治疗肺系疫病外,达原饮还可用于治疗无名发热等,但通过抑制EMT预防和/或治疗疾病的研究与应用至今未见报道。
发明内容
本发明第一方面的目的,在于依据中医理论,提供达原饮在制备抑制EMT的药物中的应用。
本发明第二发明的目的,在于提供达原饮在制备CDH1基因、E-cad蛋白促进剂中的应用。
本发明第三发明的目的,在于提供达原饮在制备N-cad或Vimentin抑制剂中的应用。
本发明第四方面的目的,在于提供达原饮在制备胶原蛋白合成抑制剂中的应用。
为了实现上述目的,本发明所采取的技术方案是:
本发明第一个方面,在于提供达原饮在制备抑制EMT的药物中的应用,所述达原饮由包括以下组分的原料制成:槟榔、厚朴、草果仁、知母、白芍、黄芩、甘草片。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~18份、厚朴3~9份、草果仁1~5份、知母3~9份、白芍3~9份、黄芩3~9份、甘草1~5份。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~10份、厚朴3~7份、草果仁1~4份、知母3~6份、白芍3~6份、黄芩3~6份、甘草1~4份。
在本发明一些实施方式中,所述药物促进发生EMT的上皮细胞中E-cad蛋白的表达,和/或抑制发生EMT的上皮细胞中N-cad、Vimentin、α-SMA蛋白的表达。
在本发明一些实施方式中,所述药物抑制发生EMT的肿瘤细胞迁移,降低细胞迁移,和/或抑制肺纤维化过程中EMT的发生,降低肺组织中的羟脯氨酸含量。
在本发明一些实施方式中,所述药物由包括所述的达原饮和药学上可接受的辅料制备而成。
在本发明一些实施方式中,所述药物可按本领域常规方法制备。本发明所述药物是各原料药粉碎后混合而成的组合物;或者各原料药混合后提取得到的提取物,或者各原料药单独提取后混合得到的提取物。任选的,提取物进一步精制纯化。其中,所述提取的方法包括煎煮提取、回流提取、浸渍提取、超声提取、渗漉提取、微波提取等:所述纯化的方法包括水提醇沉、碱溶酸沉以及各种柱色谱纯化方法,如大孔树脂柱、硅胶柱、凝胶柱、反相柱等。
在本发明一些实施方式中,所述药物的剂型为汤剂、片剂、胶囊剂、颗粒剂、丸剂、口服液、散剂和膏剂中的一种。
在本发明一些实施方式中,上述达原饮加入适宜的药学上可接受的辅料,按所需剂型的常规制备工艺即可,以制成相应的汤剂、片剂、胶囊剂、颗粒剂、丸剂、口服液、散剂和膏剂。
在本发明一些实施方式中,所述药学可接受的辅料包括填充剂、崩解剂、稀释剂、润滑剂、粘合剂、湿润剂、矫味剂、助悬剂、溶剂、缓释剂、乳化剂、吸收促进剂、表面活性剂或防腐剂中的至少一种。
在本发明一些实施方式中,所述填充剂选自淀粉、蔗糖、乳糖、甘露醇、山梨醇、木糖醇、微晶纤维素或葡萄糖等;所述粘合剂选自纤维素衍生物、藻酸盐、淀粉、水、糊精、明胶、羟丙基纤维素、甲基纤维素或聚乙烯吡咯烷酮等;所述稀释剂选自乳糖、蔗糖、甘露醇、玉米淀粉、马铃薯淀粉、磷酸钙、柠檬酸钙和结晶纤维素中的至少一种;所述崩解剂选自玉米淀粉、马铃薯淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙基纤维素、羧甲基淀粉钠、羧甲基纤维素、交联羧甲基纤维素钠、羧甲基纤维素钙和藻酸中的至少一种;所述润滑剂选自硬脂酸、聚乙二醇、碳酸钙、碳酸氢钠、微粉硅胶、滑石粉、无水硅胶和硬脂酸镁中的至少一种:所述助悬剂选自微粉硅胶、蜂蜡、纤维素、羧甲基纤维素钠和固态聚乙二醇中的至少一种:所述润湿剂选自甘油、吐温-80、氧基氢化蓖麻油、十二烷基硫酸钠和卵磷脂中的至少一种:所述溶剂选自乙醇、液态聚乙二醇、异丙醇、吐温-80、甘油、丙二醇和植物油中的至少一种,所述植物油选自大豆油、蓖麻油、花生油、调和油等:所述表面活性剂选自十二烷基苯磺酸钠、硬脂酸、聚氧乙烯-聚氧丙烯共聚物、脂肪酸山梨坦和聚山梨(吐温)中的至少一种:所述矫味剂选自阿斯巴甜、蔗糖素、香精、甜菊素、安赛蜜、柠檬酸和糖精钠中的至少一种;所述防腐剂选自对羟苯甲酸甲酯或对羟苯甲酸丙酯中的至少一种。
本发明第二个方面,在于提供达原饮在制备CDH1基因、E-cad蛋白促进剂中的应用。
在本发明一些实施方式中,所述CDH1基因、E-cad蛋白促进剂为促进CDH1基因或E-cad蛋白表达的促进剂。
在本发明一些实施方式中,所述CDH1基因、E-cad蛋白促进剂用于促进细胞内CDH1基因或E-cad蛋白的表达。
在本发明一些实施方式中,所述细胞包括肺癌细胞和肺泡上皮细胞。
在本发明一些实施方式中,所述达原饮由包括以下组分的原料制成:槟榔、厚朴、草果仁、知母、白芍、黄芩、甘草片。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~18份、厚朴3~9份、草果仁1~5份、知母3~9份、白芍3~9份、黄芩3~9份、甘草1~5份。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~10份、厚朴3~7份、草果仁1~4份、知母3~6份、白芍3~6份、黄芩3~6份、甘草1~4份。
在本发明一些实施方式中,所述促进剂由包括所述的达原饮和药学上可接受的辅料制备而成。
在本发明一些实施方式中,所述促进剂可按本领域常规方法制备。本发明所述促进剂是各原料药粉碎后混合而成的组合物;或者各原料药混合后提取得到的提取物,或者各原料药单独提取后混合得到的提取物。任选的,提取物进一步精制纯化。其中,所述提取的方法包括煎煮提取、回流提取、浸渍提取、超声提取、渗漉提取、微波提取等:所述纯化的方法包括水提醇沉、碱溶酸沉以及各种柱色谱纯化方法,如大孔树脂柱、硅胶柱、凝胶柱、反相柱等。
在本发明一些实施方式中,所述药学可接受的辅料包括填充剂、崩解剂、稀释剂、润滑剂、粘合剂、湿润剂、矫味剂、助悬剂、溶剂、缓释剂、乳化剂、吸收促进剂、表面活性剂或防腐剂中的至少一种。
本发明第三个方面,在于提供达原饮在制备N-cad或Vimentin的抑制剂中的应用。
在于提供达原饮在抑制N-cad或Vimentin的表达中的应用。
在本发明一些实施方式中,所述N-cad或Vimentin抑制剂为抑制N-cad或Vimentin基因或蛋白表达的抑制剂。
在本发明一些实施方式中,所述N-cad或Vimentin抑制剂用于抑制细胞内N-cad或Vimentin基因或蛋白表达。
在本发明一些实施方式中,所述细胞包括肺癌细胞和肺泡上皮细胞。
在本发明一些实施方式中,所述达原饮由包括以下组分的原料制成:槟榔、厚朴、草果仁、知母、白芍、黄芩、甘草片。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~18份、厚朴3~9份、草果仁1~5份、知母3~9份、白芍3~9份、黄芩3~9份、甘草1~5份。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~10份、厚朴3~7份、草果仁1~4份、知母3~6份、白芍3~6份、黄芩3~6份、甘草1~4份。
在本发明一些实施方式中,所述抑制剂由包括所述的达原饮和药学上可接受的辅料制备而成。
在本发明一些实施方式中,所述抑制剂可按本领域常规方法制备。本发明所述抑制剂是各原料药粉碎后混合而成的组合物;或者各原料药混合后提取得到的提取物,或者各原料药单独提取后混合得到的提取物。任选的,提取物进一步精制纯化。其中,所述提取的方法包括煎煮提取、回流提取、浸渍提取、超声提取、渗漉提取、微波提取等:所述纯化的方法包括水提醇沉、碱溶酸沉以及各种柱色谱纯化方法,如大孔树脂柱、硅胶柱、凝胶柱、反相柱等。
在本发明一些实施方式中,所述药学可接受的辅料包括填充剂、崩解剂、稀释剂、润滑剂、粘合剂、湿润剂、矫味剂、助悬剂、溶剂、缓释剂、乳化剂、吸收促进剂、表面活性剂或防腐剂中的至少一种。
本发明第四个方面,在于提供达原饮在制备胶原蛋白合成抑制剂中的应用。
在于提供达原饮在体外抑制胶原蛋白合成中的应用。
在本发明一些实施方式中,所述胶原蛋白合成抑制剂为抑制纤维化过程中胶原的过度合成。
在本发明一些实施方式中,所述达原饮由包括以下组分的原料制成:槟榔、厚朴、草果仁、知母、白芍、黄芩、甘草片。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~18份、厚朴3~9份、草果仁1~5份、知母3~9份、白芍3~9份、黄芩3~9份、甘草1~5份。
在本发明一些实施方式中,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~10份、厚朴3~7份、草果仁1~4份、知母3~6份、白芍3~6份、黄芩3~6份、甘草1~4份。
在本发明一些实施方式中,所述抑制剂由包括所述的达原饮和药学上可接受的辅料制备而成。
在本发明一些实施方式中,所述抑制剂可按本领域常规方法制备。本发明所述抑制剂是各原料药粉碎后混合而成的组合物;或者各原料药混合后提取得到的提取物,或者各原料药单独提取后混合得到的提取物。任选的,提取物进一步精制纯化。其中,所述提取的方法包括煎煮提取、回流提取、浸渍提取、超声提取、渗漉提取、微波提取等:所述纯化的方法包括水提醇沉、碱溶酸沉以及各种柱色谱纯化方法,如大孔树脂柱、硅胶柱、凝胶柱、反相柱等。
在本发明一些实施方式中,所述药学可接受的辅料包括填充剂、崩解剂、稀释剂、润滑剂、粘合剂、湿润剂、矫味剂、助悬剂、溶剂、缓释剂、乳化剂、吸收促进剂、表面活性剂或防腐剂中的至少一种。
本发明的有益效果是:
本发明首次公开了达原饮在制备抑制EMT的药物中的应用。通过实验证明,达原饮可有效促进发生EMT的上皮细胞中CDH1基因和E-cad蛋白的表达,抑制发生EMT的上皮细胞中N-cad、Vimentin、α-SMA蛋白的表达。抑制发生EMT的肿瘤细胞迁移,降低肿瘤细胞迁移率。抑制肺纤维化过程中EMT的发生,降低肺组织中的羟脯氨酸含量,抑制纤维化过程中胶原蛋白的过度合成。即达原饮可通过抑制EMT用于预防和/或治疗EMT相关的疾病,为EMT相关疾病的预防和治疗提供新的可能。本发明所用的达原饮的质量可控、便于标准化生产,且安全可靠、对人体无毒副作用。
附图说明
图1为达原饮质谱图。
图2为达原饮混标质谱图。
图3为达原饮药理血清对TGF-β1诱导的A549细胞中EMT相关蛋白的影响;其中,A为Western blot显示目标蛋白的表达情况;B、C、D、E分别为ImageJ分析目标蛋白的相对表达量;图中,达原饮+为低剂量药理血清,达原饮++为中剂量药理血清,达原饮+++为高剂量药理血清,*代表P<0.05,**代表P<0.01。
图4为达原饮药理血清干预TGF-β1诱导的A549细胞迁移的结果;其中,A为不同诱导时间细胞迁移的情况;B为12h的细胞迁移率,C为18h的细胞迁移率;图中,达原饮+为低剂量药理血清,达原饮++为中剂量药理血清,达原饮+++为高剂量药理血清,*代表P<0.05,**代表P<0.01。
图5为达原饮对博来霉素造模至第14天的小鼠体重、肺脏质量和肺脏系数的影响;其中,A为小鼠体重,B为肺脏质量,C为肺脏系数;图中,达原饮+为低剂量组,达原饮++为中剂量组,达原饮+++为高剂量组,*代表P<0.05,**代表P<0.01。
图6为达原饮干预博来霉素造模至第14天小鼠肺组织中CDH1基因表达的结果,图中,达原饮+为低剂量组,达原饮++为中剂量组,达原饮+++为高剂量组,*代表P<0.05,**代表P<0.01。
图7为达原饮干预博来霉素造模至第14天小鼠肺组织中E-cad蛋白表达的结果;其中,A为Western blot显示E-cad蛋白的表达情况,B为ImageJ分析目标蛋白的相对表达量;图中,达原饮+为低剂量组,达原饮++为中剂量组,达原饮+++为高剂量组,*代表P<0.05,**代表P<0.01。
图8为达原饮干预博来霉素造模第14天小鼠肺组织中E-cad蛋白免疫荧光染色的结果(标尺为50μm),图中,A为正常组,B为模型组,C为达原饮低剂量组,D为达原饮中剂量组,E为达原饮高剂量组,F为地塞米松组。
图9为达原饮干预博来霉素造模第14天小鼠肺组织中α-SMA蛋白免疫组织化学染色的结果(标尺为100μm),图中,A为正常组,B为模型组,C为达原饮低剂量组,D为达原饮中剂量组,E为达原饮高剂量组,F为地塞米松组。
图10为博来霉素造模至第21天的小鼠肺组织的HE染色结果(标尺为60μm),图中,A为正常组,B为模型组,C为高剂量达原饮组,D为地塞米松组。
图11为博来霉素造模至第21天的小鼠肺组织的Masson染色结果(标尺为60μm),图中,A为正常组,B为模型组,C为高剂量达原饮组,D为地塞米松组。
图12为博来霉素造模至第21天的小鼠右肺组织的羟脯氨酸含量的检测结果,图中,*代表P<0.05,**代表P<0.01。
具体实施方式
现结合具体实施例对本发明进行详细说明,但不限制本发明的范围。
本实施例中所使用的材料、试剂等,如无特别说明,为从商业途径得到的材料和试剂。
实施例1
根据《经典名方开发指引》中达原饮组方剂量槟榔(7.46g)、生厚朴(3.73g)、炒草果仁(1.87g)、知母(3.73g)、白芍(3.73g)、黄芩(3.73g)、生甘草(1g)共七味,购于北京燕京饮片厂。称取5倍量的全方药材,10倍量去离子水煎煮两次,每次1h,合并水煎液,减压浓缩,定容至500mL。分别取三份20ml提取液,冷冻干燥(-60℃,真空度<50pa),计算提取率,结果见表1,冻干粉制备工艺稳定,平均提取率为23.7±0.13%。剩余提取液进行冷冻干燥(-60℃,真空度<50pa),得到达原饮冻干粉。
表1达原饮冻干粉提取率
取冻干粉10mg,溶于1mL去离子水中,制备成10mg/mL样品。标准品:厚朴酚、和厚朴酚、芒果苷、知母皂苷BⅡ、芍药苷、黄芩苷、黄芩素、汉黄芩苷、黄芩素、甘草苷、甘草酸,分别配置成40μg/mL液体,各取100μL混匀,制备混标。对冻干粉样品以及混标进行质谱分析,并与数据库对比。
结果如图1和图2显示:质谱得到172种化合物,经过筛选得到106种化合物,其中包括混标中的11种标准品。
实施例2
选取8周龄的SD大鼠,适应性喂养1周后,随机分为4组,分别为对照组、达原饮低剂量组、达原饮中剂量组和达原饮高剂量组,每组3只。按分组给予达原饮冻干粉水溶液(低剂量组0.43g/mL、中剂量组0.86g/mL、高剂量组1.72g/mL)灌胃(1.35mL/天),每日1次,连续给药3天,对照组灌胃等体积饮用水,于末次灌胃1.5h后取血,制备得到达原饮药理血清。
TGF-β1(10ng/mL)诱导的A549细胞(即EMT细胞模型)给予含有10%对照血清或不同浓度的达原饮药理血清处理,48h后提取各组A549细胞的蛋白,进行Western blot检测。Western blot结果如图3显示:与模型组相比,达原饮高剂量组的大鼠药理血清能促进发生EMT的模型细胞中E-cad蛋白的表达(P<0.01),降低N-cad(P<0.01)、Vimentin(P<0.05)和α-SMA蛋白的表达量(P<0.05)。
实施例3
人肺癌细胞(A549细胞)在TGF-β1的诱导下,失去上皮细胞特征向间充质细胞转化,使癌细胞具备迁移能力。用含有10%FBS的DMEM培养基正常培养A549细胞至对数生长期,以106个/孔接种至6孔板。待细胞贴壁后划痕,PBS清洗细胞三次,加入含有2.5%对照血清或不同浓度的达原饮药理血清(实施例2制得)的DMEM培养基处理,同时添加TGF-β1(10ug/mL)。37℃、5%的CO2培养0h、12h、18h拍摄记录细胞位置。用Image J统计细胞迁移率。
结果如图4所示:达原饮中、高剂量组的药理血清能够显著降低12h和18h模型细胞的迁移率(P<0.01)。
实施例4
购置8周龄SPF级C57BL/6N雄性小鼠,适应饲养1周后,气管内滴注博来霉素(1.5mg/kg)进行造模。造模1天后,将小鼠随机分为模型组、达原饮低剂量组、达原饮中剂量组、达原饮高剂量组和阳性对照组。给药组按0.3mL/只/天灌胃达原饮冻干粉水溶液(达原饮低剂量组0.43g/mL、达原饮中剂量组0.86g/mL、达原饮高剂量组1.72g/mL),阳性对照组腹腔注射地塞米松(2mg/kg),模型组灌胃等体积饮用水,正常组常规饲养。连续给药13天后停止给药,分别于造模后第14天取材观察达原饮对肺纤维化小鼠EMT的影响,于造模后第21天取材观察达原饮对肺组织中羟脯氨酸含量的影响。
1.采用称重法测量肺脏质量和肺系数
于给药处理至造模后第14天,称量各组小鼠体重,腹腔注射戊巴比妥钠(55mg/kg)进行麻醉,腹主动脉取/放血后,取全肺称量肺湿重,计算肺脏系数=肺湿重(g)/体重(g)*100%。结果如图5所示:造模后第14天,与模型组相比,达原饮高剂量组能下调肺纤维化小鼠肺脏质量(P<0.05)和肺脏系数(P<0.05)。
2.采用qPCR分析各组小鼠肺组织中CDH1基因的表达情况
给药处理至造模后第14天,取各组小鼠右肺组织一叶,用RNA提取试剂盒(中国Accurate公司,批号:A4A2039)提取总RNA,用RNA反转录试剂盒(中国Accurate公司,批号:A4A1006)反转录为cDNA,使用Premix Ex TaqTM试剂盒(中国Accurate公司,批号:A4A1954)进行PCR扩增,以上实验均按照说明书操作。引物由生工生物工程公司(中国Sangon Biotech公司)合成,序列如下:
CDH1上游引物:5’-CAGTTCCGAGGTCTACACCTT-3’(SEQ ID NO:1)。
CDH1下游引物:5’-TGAATCGGGAGTCTTCCGAAAA-3’(SEQ ID NO:2)。
GAPDH上游引物;5’-AGGTCGGTGTGAACGGATTTG-3’(SEQ ID NO:3)。
GAPDH下游引物;5’-GGGGTCGTTGATGGCAACA-3’(SEQ ID NO:4)。
PCR扩增反应条件为:预变性(95℃,30s),PCR扩增40个循环(95℃、5s,60℃、30s)。实验结果采用mRNA相对表达量=2-ΔΔCT计算。
qPCR分析结果如图6所示:给药至造模第14天,与模型组相比,达原饮高剂量组促进肺纤维化小鼠肺的组织中CDH1基因的表达(P<0.01)。
3.采用Western blot和免疫荧光染色分析各组小鼠肺组织中E-Cad蛋白的表达情况
给药处理至造模后第14天,取各组小鼠右肺组织一叶,经组织匀浆仪裂解后,4℃、13000rpm离心5min。取裂解液上清,经BCA试剂盒测定(中国Biorigin,批号:20230104)蛋白含量,加入5×SDS上样缓冲液,95℃金属浴加热5min,制备Western blot样品。Westernblot结果如图7所示:与模型组相比,达原饮高剂量能够促进肺纤维化小鼠肺组织中E-cad蛋白的表达(P<0.01)。
取各组小鼠左肺叶灌注固定液(0.1mL/叶)。固定后的肺组织行石蜡包埋,按3μm厚度制备肺组织切片。对各组肺组织切片进行常规免疫荧光染色,FV3000激光共聚焦显微镜(日本Olympus公司)扫描图像。结果如图8所示:给药至造模第14天,对照组的E-cad蛋白广泛表达于正常肺泡隔的上皮细胞;与对照组相比,模型组的肺泡上皮细胞大量丢失E-Cad蛋白;与模型组相比,随着给药剂量增加达原饮能够促进肺纤维化小鼠肺泡上皮细胞中E-Cad蛋白的表达。
4.采用免疫组织化学染色法观察α-SMA蛋白在肺组织中的表达情况
给药处理至造模后第14天,取各组小鼠的左肺组织切片,进行常规免疫组织化学染色,DM6000B显微镜(德国Leica公司)扫描病理结果,观察肺组织中α-SMA蛋白的表达情况。结果如图9所示:模型组实变区中α-SMA蛋白呈强阳性表达,随着达原饮给药剂量增加α-SMA蛋白的阳性水平降低。
5.采用HE染色和Masson染色观察病理进展情况
第14天停止灌胃高剂量达原饮后,至造模第21天取各组小鼠的左肺组织切片,进行常规HE染色和Masson染色,DM6000B显微镜(德国Leica公司)扫描病理结果,观察肺纤维化进展。HE染色结果如图10所示:至造模第21天,正常组小鼠肺泡结构完整,肺间隔中有丰富的气-血屏障;模型组实变区内可见大量间质细胞增生,肺泡间隔增厚。高剂量达原饮能够缓解肺间质增生。Masson染色结果如图11所示:至造模第21天,正常组小鼠肺泡隔中较少观察到胶原纤维(蓝色);模型组小鼠的实变区内胶原纤维持续沉积,造成实变区大面积蓝染,高剂量达原饮能够减少实变区内胶原纤维的沉积。
6.采用羟脯氨酸检测法分析肺组织中的胶原含量
羟脯氨酸为胶原纤维所特有,测定肺组织中的羟脯氨酸含量,可以评估肺纤维化的程度。第14天停止灌胃高剂量达原饮后,至造模第21天取各组小鼠两叶右肺组织加入500μL组织裂解液,匀浆后取50μL,加12mol/mL盐酸50μL,121℃加热2h,冷却后用10mol/mL氢氧化钠调节pH至6~8范围。按试剂盒(中国solarbio,批号:20230404)说明操作加入检测试剂,60℃水浴15min,冷却,3500rpm离心10min,取上清用800TS酶标仪(美国BioTek公司)检测560nm的吸光度,并根据标准曲线计算样品中的羟脯氨酸含量。
结果如图12所示:与模型组相比,高剂量达原饮能降低肺纤维化小鼠肺组织中的羟脯氨酸含量(P<0.01),抑制纤维化过程中胶原蛋白的合成。
上面结合附图对本发明实施例作了详细说明,但是本发明不限于上述实施例,在所属技术领域普通技术人员所具备的知识范围内,还可以在不脱离本发明宗旨的前提下做出各种变化。此外,在不冲突的情况下,本发明的实施例及实施例中的特征可以相互组合。
Claims (10)
1.达原饮在制备抑制EMT的药物中的应用,所述达原饮由包括以下组分的原料制成:槟榔、厚朴、草果仁、知母、白芍、黄芩、甘草片。
2.根据权利要求1所述的应用,其特征在于,所述达原饮由包括以下重量份的组分的原料制成:槟榔6~18份、厚朴3~9份、草果仁1~5份、知母3~9份、白芍3~9份、黄芩3~9份、甘草1~5份。
3.根据权利要求2所述的应用,其特征在于,所述药物促进发生EMT的上皮细胞中CDH1基因和E-cad蛋白的表达,和/或抑制发生EMT的上皮细胞中N-cad、Vimentin、α-SMA蛋白的表达,和/或抑制发生EMT的肿瘤细胞迁移,降低细胞迁移,和/或抑制肺纤维化过程中EMT的发生,抑制胶原的合成。
4.根据权利要求1~3中任一项所述的应用,其特征在于,所述药物由包括权利要求1~3中任一项所述的达原饮和药学上可接受的辅料制备而成。
5.根据权利要求4所述的应用,其特征在于,所述药学可接受的辅料包括填充剂、崩解剂、稀释剂、润滑剂、粘合剂、湿润剂、矫味剂、助悬剂、溶剂、缓释剂、乳化剂、吸收促进剂、表面活性剂或防腐剂中的至少一种。
6.根据权利要求1~3中任一项所述的应用,其特征在于,所述药物是各原料药粉碎后混合而成的组合物;或者各原料药混合后提取得到的提取物,或者各原料药单独提取后混合得到的提取物。
7.根据权利要求1~3中任一项所述的应用,其特征在于,所述药物的剂型为汤剂、片剂、胶囊剂、颗粒剂、丸剂、口服液、散剂和膏剂中的一种。
8.达原饮在(1)或(2)中的应用:
(1)制备CDH1基因和E-cad蛋白促进剂;
(2)促进CDH1基因和E-cad蛋白的表达。
9.达原饮在(3)或(4)中的应用:
(3)制备N-cad抑制剂或Vimentin抑制剂;
(4)抑制N-cad或Vimentin的表达。
10.达原饮在(5)或(6)中的应用:
(5)制备胶原蛋白合成抑制剂;
(6)抑制胶原蛋白的合成。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311368280.7A CN117679355A (zh) | 2023-10-20 | 2023-10-20 | 达原饮在制备抑制emt的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311368280.7A CN117679355A (zh) | 2023-10-20 | 2023-10-20 | 达原饮在制备抑制emt的药物中的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117679355A true CN117679355A (zh) | 2024-03-12 |
Family
ID=90135971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311368280.7A Pending CN117679355A (zh) | 2023-10-20 | 2023-10-20 | 达原饮在制备抑制emt的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117679355A (zh) |
-
2023
- 2023-10-20 CN CN202311368280.7A patent/CN117679355A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yun et al. | Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice | |
US10624938B2 (en) | Total flavone extract of flower of abelmoschus manihot L. medic and preparation method thereof | |
WO2021203614A1 (zh) | 一种治疗冠状病毒性疾病的药物组合物及其制备方法和用途 | |
TWI300352B (en) | Water soluble extract from plant of solanum genus and the preparation process thereof, and pharmaceutical composition containing the water soluble extract | |
WO2021249420A1 (zh) | 血筒素在制备抗类风湿关节炎药物中的应用 | |
CN102526186A (zh) | 一种用于预防和治疗心血管疾病的药物组合物及其用途 | |
CN104688749B (zh) | 治疗肥胖症的女贞属苯乙醇苷类组合物及其用途 | |
WO2010081264A1 (zh) | 一种防治糖尿病肾病的药物组合物及其制备方法 | |
EP3257507A1 (en) | Application of chlorogenic acid in preparing medicines for treating lupus erythematosus | |
CN107349244B (zh) | 丙二酰基人参皂苷的提取方法 | |
CN108159204B (zh) | 一种具有解毒保肝作用的藏药组合物 | |
CN117679355A (zh) | 达原饮在制备抑制emt的药物中的应用 | |
KR100796457B1 (ko) | 생약복합제 추출물을 함유하는 당뇨병 예방 및 치료용 조성물 | |
CN113350390A (zh) | 美花风毛菊总倍半萜内酯及制备方法和其药物用途 | |
CN113893301A (zh) | 治疗肾虚血瘀证型骨质疏松的中药制剂及其制备方法 | |
CN103301167B (zh) | 满天星异荭草苷在制备治疗酒精性肝损伤药物中的应用 | |
CN116019854B (zh) | 桑提取物在制备预防和/或治疗肝胆疾病药物中的应用 | |
CN109125421A (zh) | 虎杖及虎杖苷在治疗代谢综合征中的应用 | |
CN112933070A (zh) | 一种激酶抑制剂及其在制备防治TrkA/B/C激酶异常活化导致疾病药物的用途 | |
CN105250352A (zh) | 杜仲木脂素提取物在制备肺动脉高压治疗药物中的应用 | |
CN115300586B (zh) | 一种抗尿酸盐肾沉积的中药组合物及其制备方法 | |
CN109364049A (zh) | 大黄素及大黄素与虎杖苷组合在治疗代谢综合征中的应用 | |
CN114053283B (zh) | 3β,23-O-异丙叉基羟基白桦酸在制备治疗非酒精性脂肪性肝炎药物中的应用 | |
KR20110098994A (ko) | 리퀴리티게닌 또는 이소리퀴리티게닌을 유효성분으로 포함하는 엘엑스알-알파 과다 발현으로 인한 질병의 예방 또는 치료용 조성물 | |
CN117731709B (zh) | 一种治疗前列腺炎、前列腺增生的药物及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |